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Background. The progression of human African trypanosomiasis from the early hemolymphatic stage to the late meningoen-
cephalitic stage is of critical diagnostic importance as it determines the choice of potentially toxic drug regimens. Current diagnostic 
criteria involving analysis of cerebrospinal fluid (CSF) for parasites and/or pleocytosis are sensitive, but recent evidence suggests that 
specificity may be poor.
Methods. We used an untargeted global metabolic profiling approach for the discovery of novel candidate stage-diagnostic mark-
ers in CSF from patients infected with Trypanosoma brucei rhodesiense, using 1H nuclear magnetic resonance (NMR) spectroscopy.
Results. Metabolic markers did not distinguish between early and late-stage cases but were associated with neuroinflammatory 
responses and the presentation of neurological disturbances. In particular, increased concentrations of 3-hydroxybutyrate and alanine 
and reduced concentrations of mannose and urea were discriminatory for the presentation of daytime somnolence and gait ataxia.
Conclusions. CSF metabolite concentrations provide markers for neuroinflammatory responses during central nervous system 
(CNS) invasion by trypanosomes and are associated with the presentation of neurological disturbances independently of disease 
stage determined by current criteria. This suggests that applying a dichotomous-stage diagnosis on the basis of CSF pleocytosis does 
not accurately reflect the biological changes occurring as parasites invade the CNS and has implications for biomarker discovery 
strategies.
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Human African trypanosomiasis (HAT) is caused by infection 
with the tsetse fly–transmitted hemoflagellates Trypanosoma bru-
cei rhodesiense and Trypanosoma brucei gambiense. After an initial 
hemolymphatic infection, parasites penetrate the central nervous 
system (CNS), leading to meningoencephalitis, which is fatal if 
untreated [1]. Progression from the hemolymphatic to meningo-
encephalitic stage presents a therapeutic challenge because of the 
toxic nature of drugs required once the parasites are present in the 
CNS. In T. b. rhodesiense infection, treatment requires the use of 
the trivalent arsenical melarsoprol, with serious neurological dam-
age ensuing in up to 10% of treatments and a fatal reactive enceph-
alopathy in up to 5% of treatments. In T. b. gambiense infection, 
melarsoprol treatment of the late stage has been largely replaced 
with the better-tolerated eflornithine and nifurtimox combination 
therapy, but this treatment still carries significant side effects in up 
to 2% of treatments and is logistically challenging to deliver [2].
Because of the hazards involved with treatment of the late stage 
of infection, an accurate diagnosis of stage is essential. Currently 
this involves detection of one or both of the parasites in the cere-
brospinal fluid (CSF) or a pleocytosis of the CSF >5 cell/mm3 [3]. 
However, these diagnostic criteria are now under question. In 
T. b. gambiense infection, it has been demonstrated that mod-
erate pleocytosis of the CSF, from 5 cells/µL to 20 cells/µL, 
may still be effectively treated with drugs developed for early 
stage infection [4]. In T. b.  rhodesiense HAT, neuroinflamma-
tory responses symptomatic of parasite invasion of the brain 
have been detected in cases that were also effectively treated 
with early stage drugs [5]. Furthermore, neurological symp-
toms, such as somnolence, which formerly were considered to 
be exclusive evidence of the late stage of infection, have been 
detected in a proportion of patients with early stage infection 
[6]. These clinical observations are consistent with those from 
studies of CNS invasion in experimental rodent models of HAT 
in which initial invasion takes place very early in infection and 
at a time when animals may still be effectively treated with early 
stage drugs [7, 8]. Taken together, the clinical and experimen-
tal observations indicate that the current staging criteria do not 
accurately reflect disease progression in the brain and that new, 
biologically and therapeutically relevant staging criteria are 
required in HAT.
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Metabolic profiling has been shown to be a powerful tool 
in providing key insights into the complex dynamic interplay 
between metabolic processes of both the host and the parasite, 
where parasite-related perturbations in host metabolic pathways 
may highlight different mechanisms involved in either acute or 
chronic infection [9]. We have previously used this approach to 
investigate plasma from clinical T. b. rhodesiense HAT cases and 
in experimental animal models to discover disease diagnostic 
markers and understand pathophysiological processes [10, 11]. 
A  similar approach has been described using untargeted liq-
uid chromatography mass spectrometry metabolic screening 
of plasma, urine, and CSF specimens from patients infected 
with T. b. gambiense [12]. We now describe the analysis of CSF 
from patients with T. b. rhodesiense HAT, using proton nuclear 
magnetic resonance (1H NMR) spectroscopy, a high-through-
put and robust method that is optimal for analyzing multiple 
metabolites simultaneously within complex biological mixtures 
[13, 14], including CSF [15]. Cytokine concentrations in CSF 
samples were additionally measured as markers of local inflam-
mation and were correlated with metabolite levels.
The aim of this study was to determine the relationship of 
small-metabolite markers to current staging criteria, neuroin-
flammatory processes, and the presentation of neurological 
symptoms as a strategy to discover novel diagnostic markers 
and understand the physiological processes involved in pro-
gression of HAT.
METHODS
Ethics Statement
Human CSF samples were collected from adult patients with 
suspected HAT only, following standard diagnostic meth-
ods [16] and approved by ethics committees in Uganda 
(Uganda National Council for Science and Technology refer-
ence no. 082786) and the United Kingdom (North of Scotland 
Research Ethics Committee reference no. 08/S0802/126), con-
forming to the principles of the Declaration of Helsinki. Ethical 
consent forms were designed in English and translated into 
local languages. Consent was given as a signature or a thumb-
print after verbal explanation. For those aged <18 years, consent 
was given by the legal guardian.
Patient Information and Sample Collection
Details of study sites, patient recruitment, and diagnostic 
and treatment protocols have been presented elsewhere [6, 
11]. A  total of 51 patients with HAT were recruited at Lwala 
Hospital, Kaberamaido District, and Serere Health Center, 
Serere District, in eastern Uganda, between November 2008 
and March 2010. CSF samples were collected from all patients 
as part of normal diagnostic and staging procedures. Late-stage 
cases were identified using World Health Organization staging 
criteria, consisting of the presence of parasites in the lumbar 
CSF and/or a CSF white blood cell count of >5 cells/µL [16]. 
Aliquots of 1–2 mL of CSF were immediately frozen and then 
maintained in liquid nitrogen until transferred to the United 
Kingdom via airfreight (on dry ice for 24 hours) and stored at 
–80°C until analysis. Of the original 51 CSF samples, 46 were 
available to use for subsequent metabolic analyses. A summary 
of the parasitological, demographic, and neurological charac-
teristics of the patients can be found in the results.
Metabolic Data Acquisition and Processing via 1H NMR Spectroscopy
A total of 46 CSF samples from patients with HAT underwent 
metabolic screening via 1H NMR spectroscopy. Samples were 
prepared in 1 batch in a randomized order. Prior to acquisition, 
an aliquot of 280 µL per CSF sample was diluted with 260 µL 
of distilled water and 60 μL of Bruker urine buffer (1.5 M 
K2HPO4, 2 mM NaN3, 0.1% volume/volume 3-[trimethylsilyl]
propionic-2,2,3,3-d4 acid sodium salt [TSP] solution, and 10% 
volume/volume D2O, with pH adjusted to 7.4; Sigma-Aldrich, 
Germany) in microfuge tubes. Samples were centrifuged for 1 
minute at 14 000×g, and 570 µL per sample was transferred 
into 5-mm NMR tubes. 1H NMR data were acquired (over 
3 days) on a Bruker Avance 600 MHz (14.1 T) NMR spectrom-
eter with a BB probe head and refrigerated SampleJet autosam-
pler (Bruker, Germany), using Topspin software (version 3.1, 
Bruker BioSpin, Germany). Metabolic data were acquired as 
described elsewhere [11] with the following modifications: 
acquisition via a standard 1-dimensional pulse and water sup-
pression program was performed at 310 K, with 256 acquired 
free induction decays and 4 dummy scans. Data processing 
(including automatic phasing, baseline correction, TSP ref-
erence peak calibration, automatic spectral alignment, and 
probabilistic quotient normalization) were performed using 
MATLAB (version R2013a; Mathworks) and Topspin as out-
lined by Lamour et al [11]. Spectral assignments of metabo-
lite peaks were identified using Chenomx NMR suite profiler 
8.1 software and literature references [15, 17]. Spectral peaks 
derived from the drug metabolite paracetamol (for acetamin-
ophen; 2.15 singlet [s] and 6.92 and 7.25 doublets [d]) and 
contaminant ethanol resonances (1.19 triplet [t] and 3.68 qua-
druplet [q]) were identified in a subset of samples, and these 
spectral regions were thus excluded from the entire data set.
CSF Cytokine Analysis
Interferon γ (IFN-γ), interleukin 6 (IL-6), and interleukin 10 
(IL-10) concentrations were measured using a solid-phase 
sandwich enzyme-linked immunosorbent assay (OptiEIA; BD 
Pharmingen), as described previously [18]. Biological limits of 
detection were 1.8, 8.3, and 1.6 pg/mL, respectively. When the 
cytokine concentration was lower than the lower limit of detec-
tion, a nominal concentration of 0.5 times the limit of detection 
was recorded.
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Data Analysis
Following data processing, spectral NMR files were analyzed 
using principal component analysis (PCA) and orthogo-
nal partial least squares discriminatory analysis (OPLS-DA) 
(SIMCA software, version 14.0; Umetrics, Sweden). PCA is 
an unsupervised pattern-recognition model used to evaluate 
overall variance in the data set, while OPLS-DA is a super-
vised modeling method that maximizes differences between 
groups while minimizing within-group variation and was 
used to compare profiles for patients with early infection to 
those for patients with late-stage infection [19]. In both PCA 
and OPLS-DA, samples are schematically represented as coor-
dinates on component planes and plotted on scores plots. 
Their relative positions to each other are dependent on their 
spectral similarity: samples that share similar patterns in their 
metabolic data (eg, those that have similar spectral peaks) 
are grouped together on the plot, whereas samples that show 
marked differences are segregated. The variables responsible 
for their positioning in the scores plot are shown in the corre-
sponding loadings plot. This modeling strategy was repeated, 
using the integrals of endogenous metabolites identified via 
NMR, to discriminate differentiating metabolites between 
patients with neurological manifestations (ie, somnolence, 
abnormal gait, and tremor) and those without such manifesta-
tions or with a Glasgow coma scale score of <15 and to assess 
the impact of other potential confounding factors (ie, patient 
age and sex and sample collection site).
Metabolite integrals were further analyzed via univariate 
nonparametric tests, using Mann-Whitney U tests, followed 
by Benjamini-Hochberg false-discovery rate adjustment [20] 
to correct for multiple testing. Percentage differences between 
patients stratified by stage or presence of a neurological symp-
tom were reported on the basis of the median integral values 
for each group relative to those for patients with early stage 
infection or without symptoms. Spearman-based correlation 
analysis was performed between cytokine concentrations and 
integrals of metabolites that were discriminatory for neurologi-
cal disturbances, with Benjamini-Hochberg false-discovery rate 
adjustment.
RESULTS
Patients and Symptoms
Demographic and clinical details of patients with HAT recruited 
to this study are presented in Table 1. While neurological symp-
toms were observed mainly in patients with late-stage infection, 
patients with early stage infection also exhibited tremor and gait 
abnormalities.
Inflammatory and regulatory cytokine concentrations were 
also measured in a subset of CSF samples. These were selected 
purely on the basis of having sufficient residual volume to allow 
quadruplicate enzyme-linked immunosorbent assays and hence 
may be regarded as a random sample (comprising 8 of 11 early 
stage cases and 19 of 31 late-stage cases). Progression from early 
to late-stage infection was associated with significant increases 
in IL-6, IFN-γ, and IL-10 concentrations (Table 2).
Metabolic Phenotype in Early and Late-Stage HAT
The metabolic profiles in CSF samples collected from patients 
with HAT were screened using a standard 1-dimensional 1H 
NMR pulse program, a common method for detecting and quan-
tifying a wide range of complex biological molecules. Using this 
technology, we identified the peaks of 27 endogenous metab-
olites, comprised largely of sugars, amino acids, amines, and 
organic acids, with relatively low levels of lipid and protein res-
onances (Supplementary Table  1). Two exogenous metabolites 
were also detected (ie, paracetamol/acetaminophen and ethanol 
peaks), which were removed from all spectra prior to analyses.
To discover metabolite patterns that may be associ-
ated with disease state, multivariate analysis of the NMR 
peak integral data was undertaken using PCA, followed by 
OPLS-DA. Results from multivariate analyses of NMR data 
demonstrated that the inherent variability within the meta-
bolic phenotype of CSF samples was not associated with diag-
nostic stage classification of HAT. PCA models using either 
complete spectra (Figure 1) or integrals from the aforemen-
tioned 27 metabolites (Supplementary Figure 1) did not show 
any separation between the metabolic profiles from patients 
with early stage and those with late-stage infections, indi-
cating that both groups display strong similarities in their 
metabolic profiles and that the variance within the sample 
set is not driven by stage of infection. Further comparisons 
between stages using discriminant multivariate analyses (ie, 
OPLS-DA [Supplementary Figure 1]), to enhance potential 
subtle differences between these groups, and univariate non-
parametric tests (Supplementary Table 1) did not reveal any 
significant differences. Furthermore, no significant differ-
ences in metabolite signatures were observed with respect to 
patient sex, patient age, or sample collection site. PCA anal-
yses revealed that inherent variance was largely attributed to 
Table  1. Demographic Characteristics and Central Nervous System 
(CSF) Symptoms Among Patients With Early or Late-Stage Human African 
Trypanosomiasis
Characteristic
Early Stage 
(n = 11)
Late Stage 
(n = 31)
Sex, male:female 3:8 14:17
Age, y, median (range) 25 (15–70) 26 (3–70)
CSF WBC count, cells/µL, median 
(IQR)
4 (3–4) 38 (15–119)
Comaa 0 6
Gait abnormality 1 16
Tremor 2 12
Somnolence 0 14
Abbreviations: IQR, interquartile range; WBC, white blood cell.
aDefined as a Glasgow coma scale score of <15.
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differences in CSF concentrations of glutamine, creatinine, 
myo-inositol, and 3-hydroxyisovalerate.
Metabolic Phenotype Discriminates Patients Exhibiting Neurological 
Symptoms
PCA and OPLS-DA were used to investigate association 
between the CSF metabolic markers and the presence or absence 
of neurological symptoms in patients, including somnolence, 
gait impairment, tremor, and impairment of consciousness as 
measured by the Glasgow coma scale score. Differences in met-
abolic phenotypes were observed between somnolent and non-
somnolent patients, demonstrated by partial vertical separation 
between 2 groups along the first component in both models, 
although particularly in OPLS-DA (Figure 2). Examination of 
the corresponding OPLS-DA loadings plot revealed that lev-
els of lactate and the ketone body 3-hydroxybutyrate (3-HB) 
were higher in patients displaying somnolence, who also had 
lower levels of a range of sugars, including mannose and glu-
cose, and amines, such as glucosamine and dimethylamine, 
creatinine, and urea. Similar results were also observed for the 
presence or absence of gait abnormalities in patients, including 
higher levels of lactate and 3-HB and lower levels of mannose in 
patients with gait abnormalities, compared with those without 
gait impairment (Supplementary Figure 2). PCA did not reveal 
any distinction in metabolic profiles between patients with and 
those without tremors or an abnormal Glasgow coma scale 
score, nor were their corresponding discriminant OPLS-DA 
models predictive.
Somnolence and Gait Abnormalities Marked by Alterations in Ketone 
Bodies and Reduced Levels of Mannose
Nonparametric analyses of individual metabolite concentra-
tions confirmed results observed in multivariate analyses, with 
significant differences observed between patients present-
ing with and those presenting without somnolence and gait 
impairment, as shown in Table 3. Patients with abnormal gait 
displayed lower concentrations of myo-inositol than those with 
no gait impairment, whereas somnolent patients had decreased 
levels of acetone in their CSF than alert patients. Additionally, 
increases in 3-HB and alanine concentrations and decreases 
in mannose and urea concentrations were significant for both 
somnolent patients and those with gait abnormalities. No sig-
nificant differences in metabolite concentrations were found 
when the presence of tremor or an abnormal Glasgow coma 
scale score were the grouping variables.
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Figure 1. Inherent variation in cerebrospinal fluid (CSF) metabolic phenotypes is not associated with human African trypanosomiasis diagnostic stage. Principle component 
analysis scores plotted on the basis of 1H nuclear magnetic resonance spectral data of CSF samples show overlap of spectral data from patients with early stage disease 
(n = 11) and those with late-stage disease (n = 31), using the first 2 components (A) and the second and third components (B). R2X denotes the model fit parameter for variation 
in spectral data and describes the fraction of variance explained by model. Q2X denotes the model predictive parameter for spectral data and describes the predictive power 
of the model.
Table 2. Cytokine Concentrations in Cerebrospinal Fluid (CSF) Samples 
From Patients With Early or Late-Stage Human African Trypanosomiasis
Stage
Concentration, pg/mL, Median (IQR)
IL-6 IFN-γ IL-10
Early (n = 8a) 4.1 (4.1–4.1)b 0.9 (.9–11.5)b 15.7 (.8–87.0)
Late (n = 19a) 30.1 (2.8–185.4)c 25.1 (7.0–38.4)d 224.2 (87.3–515.3)d
Abbreviations: IFN-γ, interferon γ; IL-6, interleukin 6; IL-10, interleukin 10; IQR, interquartile 
range.
aData are a subset of total samples because of limited CSF volumes.
bData are reported as the lower limit of detection times 0.5.
cP < .05 by the Mann-Whitney U test, compared with early stage cases
dP < .01 by the Mann-Whitney U test, compared with early stage cases.
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Metabolites Discriminatory for Neurological Symptoms Are Associated 
With CNS Immune Activation
CSF concentrations of IL-10, IL-6, and IFN-γ were significantly 
increased in patients with late-stage infection, compared with 
those with early stage infection (Table 2). We therefore exam-
ined whether there was an association between any of the meta-
bolic markers discriminatory for neurological disturbances and 
immune activation. Several metabolites that had been shown to 
have significantly altered levels in patients presenting with som-
nolence and/or gait abnormalities exhibited significant rela-
tionships with markers of CNS immune activation (Figure 3). 
Both IL-10 and IL-6 were negatively correlated with mannose, 
myo-inositol, and urea, with IL-10 being additionally positively 
correlated with 3-HB and lactate. Interestingly, mannose was 
found to be significantly negatively correlated with all 3 cyto-
kines, as well as with white blood cell count.
DISCUSSION
In this study, an untargeted 1H NMR metabolic profiling 
approach was used to characterize the small-metabolite pro-
files in CSF samples for patients with HAT in different stages of 
disease progression. It was anticipated that these would inform 
discovery programs for new diagnostic biomarkers and provide 
candidate metabolic pathways associated with the neuropatho-
genesis of this disease. However, no metabolites were detected 
that could distinguish early from late-stage cases. Instead, a sub-
set of metabolites was found to be discriminatory for patients 
exhibiting neurological signs of infection. In particular, patients 
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Figure 2. Metabolic changes in cerebrospinal fluid (CSF) associated with somnolence. A, Principle component analysis score plot, comparing metabolic phenotypes 
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score plot (B) and corresponding loadings plot (C). Partial separation between the 2 groups along the first component is apparent across both models. NAG, N-acetyl 
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presenting with both daytime somnolence and gait abnormal-
ities exhibited higher levels of 3-HB and alanine and reduced 
levels of mannose and urea. Additionally, patients present-
ing with either of these symptoms also exhibited higher CSF 
concentrations of lactate and lower levels of myo-inositol and 
acetone. These differences appear to be independent to those 
of plasma metabolite profiles previously described [11], where 
alanine concentrations, for instance, were lower in patients than 
controls, and myo-inositol levels were higher.
The mechanisms underpinning these metabolite changes 
are not defined and are likely to be complex and related to the 
activation of the cellular immune response in the CNS. In this 
respect, the relationships demonstrated between metabolites 
discriminatory for neurological symptoms and CSF inflamma-
tory cytokines provide further evidence for the role of immuno-
logical disturbance in HAT neuropathogenesis. Progression in 
HAT has previously been shown to be associated with increases 
in levels of inflammatory cytokines, as well as the counterin-
flammatory cytokine IL-10 [5], as was confirmed in this study. 
The close correlation of IL-6 and IL-10 responses has also been 
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Figure 3. Metabolites discriminatory for patient neurological symptoms corre-
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rate–corrected Spearman-ranked correlation coefficient matrix shows statistically 
significant (P < .05) positive and negative correlations. 3-HB, 3-hydroxybutyrate; 
IL-6, interleukin 6; IL-10, interleukin 10; IFN-γ, interferon-γ; m-inositol, myo-inositol; 
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Table 3. Alterations in Metabolite Concentrations in Cerebrospinal Fluid (CSF) Samples From Patients With Neurological Symptoms
Metabolite
GCS Score <15 Gait Tremors Somnolence
Differencea Pb Differencea Pb Differencea Pb Differencea Pb
2-HB –2.3 NS –6.7 NS –11.0 NS –12.2 NS
2-HIV 0.3 NS –1.7 NS –10.3 NS –7.5 NS
3-HB 8.8 NS 17.2 .028 6.8 NS 11.6 .0351
3-HIV –10.5 NS –15.5 NS –12.2 NS –23.0 NS
Acetate –24.2 NS –17.5 NS –10.7 NS 29.9 NS
Acetone –12.4 NS –7.1 NS 13.4 NS –24.9 .034
Alanine 29.3 NS 24.2 .007 2.0 NS 24.0 .012
Citrate 6.8 NS –10.5 NS –5.6 NS –7.4 NS
Creatine –3.9 NS –3.8 NS –10.1 NS –3.3 NS
Creatinine –32.8 NS –13.2 NS –0.8 NS –18.9 NS
Dimethylamine –23.4 NS –21.9 NS 0.4 NS –28.6 NS
Formate 3.5 NS 2.3 NS –2.8 NS 4.3 NS
Gluconate –3.5 NS 2.3 NS –2.8 NS 4.3 NS
Glucose –50.7 NS –27.7 NS –8.2 NS –28.5 NS
Glutamine –34.8 NS –19.9 NS –13.2 NS –21.0 NS
Histidine –4.4 NS –8.2 NS –7.9 NS –3.7 NS
Lactate 32.5 NS 36.0 .045 18.8 NS 22.0 NS
Lysine 0.6 NS 5.4 NS 0.7 NS –2.0 NS
Mannose –45.7 NS –43.0 .003 –23.9 NS –38.9 .008
scyllo-Inositol –14.6 NS –6.6 NS 3.4 NS –20.1 NS
myo-Inositol –42.7 NS –26.4 .045 –19.9 NS –16.7 NS
NAG –20.9 NS –5.0 NS –2.5 NS –6.5 NS
Phenylalanine –8.2 NS –14.5 NS –14.3 NS –10.5 NS
Pyruvate 20.0 NS 34.5 NS 14.6 NS –15.6 NS
Tyrosine 4.3 NS –3.0 NS –7.1 NS –1.2 NS
Urea –34.5 NS –39.7 .045 –22.3 NS –44.7 .018
Valine 23.5 NS 6.9 NS –2.2 NS 3.1 NS
Concentrations were determined via 1H nuclear magnetic resonance spectroscopy. 
Abbreviations: GCS, Glasgow coma scale; HB, hydroxybutyrate; HIV, hydroxyisovalerate; NAG, N-acetyl glycoprotein; NS, not significant.
aData are percentage differences relative to values for symptomless patients.
bBy the Mann-Whitney U test with false-discovery rate correction.
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observed in rodent infection models [21] and has been pro-
posed to reflect the operation of an immunological homeostatic 
feedback mechanism in the brain [22]. Mannose, myo-inositol, 
and urea, all negatively associated with neurological distur-
bance, were found to be also significantly negatively correlated 
with CNS IL-6 and IL-10 responses. Similarly, 3-HB and lactate, 
which were positively associated with neurological disturbance, 
were also positively correlated with the CSF IL-10 concentra-
tion. This represents the first evidence linking neurological 
symptoms, the immune response, and metabolite changes in 
the CNS during infection.
Changes observed with ketone bodies such as 3-HB and ace-
tone, alanine, and/or myo-inositol concentrations in CSF have 
been shown to be discriminatory for other neuroinflammatory 
diseases, including meningitis [23, 24] and hepatic encepha-
lopathy [25, 26], but are also seen in other neurodegenerative 
diseases, such as Parkinson disease [27]. The large reduction 
in urea concentration associated with neurological symptoms 
might reflect changes in macrophage arginine metabolism 
resulting from a parasite-driven type 1 activation [28, 29].
The lack of clear discrimination of disease stage by CSF 
metabolites is consistent with our recent observations of 
kynurenine pathway activation in the CNS [30] and with a 
recent untargeted liquid chromatography mass spectrometry 
study of CSF from patients infected with T. b. gambiense, where 
metabolic signatures were only discriminatory between early 
and an advanced late stage of disease defined by CSF white 
blood cell concentrations of >20 cells/µL [12]. Thus, metabolic 
alterations and neuroinflammatory activation appear to be pre-
dictive of neurological sequelae in HAT but not of diagnostic 
stage. This highlights a major challenge for biomarker discovery 
in HAT staging and raises the question of whether the current 
empirically derived CSF white blood cell count diagnostic cri-
teria can effectively be used as an objective reference standard 
in such work.
While a range of CSF cytokines [31], chemokines [32], 
and metabolites [33] have demonstrated stage discriminatory 
potential, a common problem is a lack of specificity. This may 
be due to the onset of CNS inflammatory activity shortly after 
parasite infection (ie, during early stage infection as defined by 
current criteria). This idea is supported by our observations of 
CNS immune activation in T. b.  rhodesiense–infected patients 
who were correctly identified as having early stage infection, 
based on current diagnostic criteria (as they were treated suc-
cessfully with suramin, without relapse), and yet who presented 
neurological sequelae, including impairment of consciousness 
[5]. Thus, functional disturbances in the CNS as evidenced 
here by small-metabolite perturbations and neurological symp-
toms may precede the onset of late-stage infection as defined 
by current diagnostic criteria, and conversely it is possible that 
those cases defined as late-stage infections but not exhibiting 
CNS metabolite changes and neurological symptoms might be 
amenable to early stage drug treatment. Such fluidity in stage 
progression would be consistent with recent studies in animal 
models in which trypanosomes locate in the CNS very early 
after experimental infection [7, 34].
In conclusion, we have used metabolic profiling to reveal 
subtle changes in CSF during disease progression in HAT. CSF 
metabolites correlated with neuroinflammation and the presen-
tation of neurological disturbances independently of disease 
stage. This suggests that the currently used dichotomous-stage 
diagnosis based on CSF pleocytosis does not accurately reflect 
the biological changes occurring as parasites invade the CNS 
and indicates the potential of metabolic profiling in new bio-
marker discovery strategies.
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